Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC002646 | Panoply™ Human CCND1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC002646 | Panoply™ Human CCND1 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT1660 | Human CCND1 Knockout Cell Line-HeLa | Inquiry |
| CLKO-0007 | CCND1 KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD03254Z | Human CCND1 adenoviral particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG151957 | shRNA set against Mouse Ccnd1(NM_007631.2) | Inquiry |
| SHG151993 | shRNA set against Rat Ccnd1(NM_171992.4) | Inquiry |
| SHG152011 | shRNA set against Human CCND1(NM_053056.2) | Inquiry |
| SHH257833 | shRNA set against Human CCND1 (NM_053056.2) | Inquiry |
| SHH257837 | shRNA set against Mouse CCND1 (NM_007631.2) | Inquiry |
| SHH257841 | shRNA set against Rat CCND1 (NM_171992.4) | Inquiry |
| SHW005876 | shRNA set against Chicken CCND1 (NM_205381) | Inquiry |
| SHW014540 | shRNA set against Danio rerio CCND1 (NM_131025) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFR014688 | Rat Ccnd1 cDNA Clone(NM_171992.4) | Inquiry |
| MiUTR1H-01817 | CCND1 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-02685 | CCND1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-00808 | CCND1 miRNA 3'UTR clone | Inquiry |
| SKO0927 | CCND1 Validated sgRNA vector | Inquiry |
| CDCB167351 | Chicken CCND1 ORF Clone (NM_205381) | Inquiry |
| CDCB176015 | Danio rerio CCND1 ORF Clone (NM_131025) | Inquiry |
| CDCL183134 | Mouse CCND1 ORF clone(NM_007631.2) | Inquiry |
| CDCL183865 | Human Cyclin D1 ORF clone(NM_053056.2) | Inquiry |
| CDCR381569 | Rat Ccnd1 ORF Clone(NM_171992.4) | Inquiry |
| CDCS416601 | Human CCND1 ORF Clone (BC007782) | Inquiry |
| CDCS418283 | Human CCND1 ORF Clone (BC023620) | Inquiry |
| CDCS418284 | Human CCND1 ORF Clone (BC000076) | Inquiry |
Recent Research Progress
Cyclin D1 (encoded by the CCND1 gene) is a G1 cyclin that is important for regulating the transition of G1 to S (G1-S) in different cell types. By cooperating with its binding partners CDK4 and CDK6, CCND1 promotes phosphorylation of retinoblastoma proteins, resulting in activation of the E2F transcription factor; thus, the cell cycle is passed through G1 into the S phase. Overexpression of CCND1 is commonly observed in various types of human cancers, including HCC, and serves a critical role in the initiation of carcinogenesis. CCND1 is also involved in abnormal cell growth processes, angiogenesis and resistance to apoptosis, making it a potential therapeutic target for tumor growth.
CCND1 and T-cell lymphoma
Adult T-cell lymphoma is a highly invasive T-cell malignancy. The study found that CCND1 levels were significantly elevated compared to adjacent non-tumor tissues, and miR-373 levels were significantly reduced in T-cell lymphoma tissues. Moreover, low miR-373 levels were associated with poor patient survival. Overexpression of miR-373 significantly inhibited cell growth, while consumption of miR-373 increased cell growth in T cell lymphoma cells. Furthermore, the effect of miR-373 on cell growth appeared to be caused by changes in cell proliferation. Finally, miR-373 was found to bind to the 3'-UTR of CCND1 mRNA to inhibit its translation in T cell lymphoma cells. In conclusion, a decrease in miR-373 levels in T-cell lymphoma tissue may contribute to the growth of T-cell lymphoma by CCND1-mediated cell proliferation.
CCND1 and CRC
Colorectal cancer (CRC) is one of the most common malignant gastrointestinal cancers, and its morbidity and mortality are on the rise. MicroRNA-374a (miR-374a) exhibits carcinogenic function in various tumor types. MiR-374a acts as a tumor suppressor by inactivating PI3K/AKT signaling and downstream signaling. This negative regulation was achieved by directly reducing CCND1 to inhibit proliferation, invasion and migration in colon cancer cells (Fig. 1). Furthermore, high miR-374a and low CCND1 expression in patient samples correlated with favorable outcomes, suggesting that miR-374a and CCND1 may be useful prognostic biomarkers.

Figure 1. Potential signaling pathway utilized by miR-374a to suppress proliferation, invasion and migration in colon cancer. (Qin AC, et al, Biochemical and Biophysical Research Communications, 2015)
CCND1 and OS
Metastasis is the leading cause of death in patients with osteosarcoma (OS). Overexpression of miR-195 has been reported to substantially inhibit the migration and invasion of OS cells in vitro and the formation of lung metastases in vivo. At the same time, CCND1 was identified as a target gene of miR-195 and further studied. Studies have indicated that low expression of miR-195 or high CCND1 was associated with positive overall survival and their expression inverse relate to each other. In conclusion, miR195 acts by down-regulating CCND1 as a tumor metastasis suppressor gene and can be used as a potential target for the treatment of OS.
CCND1 and HCC
The long non-coding RNA, homeobox transcript antisense RNA (Hotair), has been shown to play an important role in the regulation of various biological processes in hepatocellular carcinoma (HCC). Knockdown of HOTAIR expression by RNA interference inhibited cell proliferation and induces G0/G1 cell cycle arrest in Huh7 hepatocyte cancer cells. In addition, the expression levels of CCND1 mRNA and its CCND1 protein product were decreased in Huh7 cells after HOTAIR knockdown. Knockdown of HOTAIR reduced expression of phosphorylation signal transducer and activator of transcription 3 (STAT3), and binding of HOTAIR knockdown to STAT3 inhibition resulted in an additional decrease in CCND1 expression. The present studies have shown that Hotair may play a key role in the proliferation of liver cancer by regulating cell cycle, STAT3 activity and CCND1 expression. Therefore, Hotair may be a new potential therapeutic target for HCC therapy.
In conclusion, amplification and overexpression of CCND1 is frequently observed in a variety of tumors, which alters cell cycle progression. Therefore, further study of the mechanism of CCND1 in various cancers will provide new insights and new targets for the diagnosis and treatment of cancer.
References: